NASDAQ: HROWHarrow Inc Stock Ownership - Who owns Harrow?
Insider buying vs selling
Have Harrow Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Opaleye Management Inc | 10% Owner | 2025-06-10 | 15,000 | $30.80 | $462.03kSell |
| Opaleye Management Inc | 10% Owner | 2025-06-09 | 15,204 | $30.37 | $461.79kSell |
| Opaleye Management Inc | 10% Owner | 2025-06-04 | 1,796 | $30.02 | $53.91kSell |
| Opaleye Management Inc | 10% Owner | 2025-06-03 | 3,000 | $30.04 | $90.12kSell |
| Opaleye Management Inc | 10% Owner | 2025-05-13 | 5,000 | $26.59 | $132.95kSell |
| Opaleye Management Inc | 10% Owner | 2025-05-12 | 10,000 | $25.90 | $258.96kSell |
| John P. Saharek | CEO President ImprimisRx | 2025-04-07 | 109,475 | $23.09 | $2.53MSell |
| Andrew R. Boll | Chief Financial Officer | 2025-04-07 | 136,745 | $23.09 | $3.16MSell |
| Mark L. Baum | Chief Executive Officer | 2025-04-07 | 300,363 | $23.09 | $6.94MSell |
| Opaleye Management Inc | 10% Owner | 2025-03-24 | 5,000 | $30.01 | $150.06kSell |
HROW insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when HROW insiders and whales buy or sell their stock.
HROW Shareholders
What type of owners hold Harrow Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Mark L. Baum | 51.60% | 18,936,133 | $573.95M | Insider |
| Robert J. Kammer | 45.06% | 16,535,872 | $501.20M | Insider |
| Opaleye Management Inc | 17.23% | 6,322,199 | $191.63M | Insider |
| Opaleye Management Inc | 10.78% | 3,955,000 | $119.88M | Institution |
| Blackrock Inc | 7.01% | 2,573,051 | $77.99M | Institution |
| Alexej Ladonnikov | 5.41% | 1,984,156 | $60.14M | Insider |
| Juliet Singh | 5.32% | 1,954,125 | $59.23M | Insider |
| Private Capital Management LLC 1 | 5.15% | 1,890,627 | $57.30M | Institution |
| Vanguard Group Inc | 5.08% | 1,865,449 | $56.54M | Institution |
| Jeffrey J. Abrams | 4.38% | 1,608,427 | $48.75M | Insider |
HROW vs Pharmaceutical Stocks
Harrow Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.